TIR-01

About Tirmed Pharma

TIRmed Pharma is a preclinical-stage biotech developing TIR-01, a topical oligonucleotide cream for atopic dermatitis. The compound aims to break the itch-scratch cycle through a unique immunomodulatory mechanism that temporarily inhibits mast cell degranulation and promotes IL-10 production, offering potential for intermittent dosing and sustained effect. With a seasoned leadership team and strategic partnerships with Bachem and Zelmic, the company is positioning itself to address a significant unmet need in the mild-to-moderate eczema market, particularly for pediatric and young adult populations.

Therapeutic Areas